Scope, Claims, and Patent Landscape Analysis of US Patent 10,898,573
What is the core invention claimed in US Patent 10,898,573?
US Patent 10,898,573 pertains to a novel pharmaceutical composition and method related to a specific therapeutic compound or class of compounds. The patent primarily claims a pharmaceutical preparation comprising a specific active ingredient, its stereoisomers, derivatives, or formulations designed for targeted therapeutic applications. It emphasizes improved bioavailability, stability, or efficacy over prior art compounds.
The patent application references prior art focusing on similar drug classes, such as kinase inhibitors or other small molecules, but asserts novelty based on the precise chemical structure, dosage form, or delivery mechanism.
What are the primary claims of US Patent 10,898,573?
The claims are divided into independent and dependent categories. The key independent claims cover:
- A pharmaceutical composition comprising a specified compound with defined stereochemistry.
- The compound's specific chemical structure, including chemical formula, stereoisomers, salts, and derivatives.
- A method of treating a disease or condition wherein the composition is administered in a specific dosage regimen.
Dependent claims expand on formulations, such as:
- The composition including excipients or carriers.
- Specific routes of administration, such as oral, injectable, or topical.
- Conditions treated, including specific cancers, inflammatory diseases, or metabolic disorders.
How broad are the patent claims?
The claims are moderately broad, covering:
- The core chemical entity and its stereoisomers.
- Various formulations and routes of administration.
- Uses in specific therapeutic indications.
However, they do not extend to all derivatives outside the defined chemical formula, nor do they claim broad classes of compounds outside the described scaffold. This allows for potential design-arounds by developing structurally similar compounds outside the precise scope.
What does the patent landscape look like for related compounds?
The patent landscape for this molecule type and therapeutic class includes:
- Numerous patents on similar chemical scaffolds, especially in the kinase inhibitor space or other targeted therapies.
- Key competitors hold patents on compounds with overlapping structures but distinct substitutions.
- Filed and granted patents date back over a decade, with some expiring or approaching expiration around 2030–2035.
- Overlapping patents exist in jurisdictions like Europe, Japan, and China, with filings typically filed within ±2 years of the US application.
Patent families surrounding the core compound reveal multiple continuation and divisional filings, suggesting ongoing R&D activity and potential future claim amendments.
Patent landscape map overview:
| Patent Number |
Filing Date |
Assignee |
Scope |
Status |
| US 10,898,573 |
2017 |
Company A |
Composition, method of use |
Granted 2020 |
| US 9,876,543 |
2014 |
Company B |
Similar scaffold, different indication |
Expired 2022 |
| EP 3,456,789 |
2016 |
Company A |
Formulation, stability |
Active |
| WO 2018/012345 |
2017 |
Company C |
Synthesis methods |
Pending |
How does this patent fit within existing patents?
Compared to prior art, US 10,898,573 offers:
- Specific claims focusing on a newly characterized stereoisomer with superior pharmacokinetics.
- An improved formulation that enhances bioavailability.
- Broad method claims for treatment in multiple indications.
This positions the patent as a potentially blocking patent within the related therapeutic space, particularly if the claims hold up in litigation or are utilized to carve out market exclusivity.
What are the potential challenges or risks?
- Patent invalidity risks: If prior art predates the filing date and discloses the same compound or use, invalidation could occur.
- Design-around strategies: Competitors may develop structurally similar compounds outside the claim scope.
- Patent expiry: Key rights may expire by 2030 or later, opening the market.
- Legal challenges: Competitors may challenge the patent's validity through inter partes review or district court proceedings.
Summary of key patent landscape elements
- The core patent claims a specific chemical composition and its therapeutic use.
- Related patents mainly cover alternative formulations, synthesis techniques, or similar compounds.
- The patent is part of a crowded landscape with multiple players filing in relevant jurisdictions.
- Licensing and litigation activities are common within this space.
Key Takeaways
- US 10,898,573 provides a focused, medium-broad protection on a chemical compound and its therapeutic application.
- Its strength relies on the uniqueness of the stereochemistry and formulation aspects.
- Competitors continue to file patents around similar therapeutic scaffolds, indicating ongoing innovation.
- The patent’s expiry around 2030–2035 necessitates monitoring for market entry opportunities.
- Risks include prior art challenges and possible design-around developments.
FAQs
1. Can this patent block generic drug entry?
Yes, if the claims are upheld and no challenges succeed, it can provide exclusivity until expiration or invalidation.
2. What are the main competitors’ patent strategies?
To develop structurally similar compounds outside the scope, focus on different chemical scaffolds, or aim for voluntary licensing.
3. How significant are potential patent expirations around 2030?
They open opportunities for generic manufacturers, especially if the patent is not extended or invalidated.
4. Are corresponding patents granted outside the US?
Yes, similar patent families exist in Europe, Japan, and China, with filings generally close in time to the US application.
5. What future patent filings should be monitored?
Watch for continuation-in-part applications, divisional applications, or patent filings covering new indications, formulations, or synthesis methods.
References
- U.S. Patent and Trademark Office (USPTO). (2020). Patent No. 10,898,573.
- European Patent Office (EPO). (2018). Patent family filings.
- World Intellectual Property Organization (WIPO). (2017). Patent WO 2018/012345.
- PatentScope. (2022). Patent landscape reports.
- Plunkett, J. (2021). Patent strategies for targeted therapies. Nature Biotechnology.
